Development of isogenic models of marginal zone lymphoma for therapeutic target discovery in TET2-deficient disease
Por:
Zhang, FW, Cascione, L, Napoli, S, Tarantelli, C, Civanelli, E, Sartori, G, Guidetti, F, Arribas, AJ, Spriano, F, Tiwari, A, Zucca, E, Alimonti, A, Rossi, D, Jha, BK, Esteller, M, Mensah, AA and Bertoni, F
Publicada:
22 oct 2025
Resumen:
Filiaciones:
Zhang, FW:
USI, Inst Oncol Res, Fac Biomed Sci, Bellinzona, Switzerland
Cascione, L:
USI, Inst Oncol Res, Fac Biomed Sci, Bellinzona, Switzerland
Napoli, S:
USI, Inst Oncol Res, Fac Biomed Sci, Bellinzona, Switzerland
Tarantelli, C:
USI, Inst Oncol Res, Fac Biomed Sci, Bellinzona, Switzerland
Civanelli, E:
USI, Inst Oncol Res, Fac Biomed Sci, Bellinzona, Switzerland
Sartori, G:
USI, Inst Oncol Res, Fac Biomed Sci, Bellinzona, Switzerland
Guidetti, F:
USI, Inst Oncol Res, Fac Biomed Sci, Bellinzona, Switzerland
Arribas, AJ:
USI, Inst Oncol Res, Fac Biomed Sci, Bellinzona, Switzerland
Spriano, F:
USI, Inst Oncol Res, Fac Biomed Sci, Bellinzona, Switzerland
Tiwari, A:
Cleveland Clin, Taussig Canc Inst, Ctr Immunotherapy & Precis Immunooncol, Cleveland, OH USA
Cleveland Clin, Taussig Canc Inst, Dept Hematol & Oncol Res, Cleveland, OH USA
Zucca, E:
USI, Inst Oncol Res, Fac Biomed Sci, Bellinzona, Switzerland
Alimonti, A:
USI, Inst Oncol Res, Fac Biomed Sci, Bellinzona, Switzerland
Rossi, D:
USI, Inst Oncol Res, Fac Biomed Sci, Bellinzona, Switzerland
Jha, BK:
Cleveland Clin, Taussig Canc Inst, Ctr Immunotherapy & Precis Immunooncol, Cleveland, OH USA
Cleveland Clin, Taussig Canc Inst, Dept Hematol & Oncol Res, Cleveland, OH USA
:
Josep Carreras Leukaemia Res Inst, Barcelona, Spain
Mensah, AA:
USI, Inst Oncol Res, Fac Biomed Sci, Bellinzona, Switzerland
Bertoni, F:
USI, Inst Oncol Res, Fac Biomed Sci, Bellinzona, Switzerland
|